CK Life Sciences Reports Profit Plunge, Advances Trials

CK Life Sciences International (Holdings), Inc. (HK:0775) has released an update.

CK Life Sciences International (Holdings) Inc. reported a sharp 97% decrease in profit attributable to shareholders for the first half of 2024, with no interim dividend declared. Despite setbacks, including COVID-related disruptions, the company is advancing its cancer vaccine, seviprotimut-L, towards a Phase III clinical trial and is developing a non-opioid analgesic, Halneuron®, for cancer pain management, with trials underway in multiple countries.

For further insights into HK:0775 stock, check out TipRanks’ Stock Analysis page.